Pure Global
NCT06258408

A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Profiles and Efficacy of Oral BB102 Tablets in Patients With Advanced Solid Tumors
BrodenBio Co., Ltd.·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Advanced Solid Tumor
Drug/Device/Intervention
BB102 tablet
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
BrodenBio Co., Ltd.
Location
Guangzhou,Zhengzhou, China
Timeline & enrollment
Phase
Phase 1
Start date
Dec 29, 2022
End date
Jul 01, 2025
Enrollment
78 participants
Primary outcome

Number of subjects with dose limiting toxicities (DLTs),Number of subjects with adverse events (AEs) and serious adverse events (SAEs)

Summary

This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, efficacy and
 preliminary food effect of BB102, a highly selective and potent FGFR4 inhibitor, as
 monotherapy in subjects with advanced solid tumors. This study has two phase: dose escalation
 phase and expansion phase.

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm: PrepuceMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissue
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06258408
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06258408 through Pure Global AI's free database. This Phase 1 trial is sponsored by BrodenBio Co., Ltd. and is currently Recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 78 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.